Becton Dickinson Gross Profit 2010-2024 | BDX
Becton Dickinson annual/quarterly gross profit history and growth rate from 2010 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Becton Dickinson gross profit for the quarter ending June 30, 2024 was $2.307B, a 9.86% increase year-over-year.
- Becton Dickinson gross profit for the twelve months ending June 30, 2024 was $8.340B, a 2.4% decline year-over-year.
- Becton Dickinson annual gross profit for 2023 was $8.17B, a 3.62% decline from 2022.
- Becton Dickinson annual gross profit for 2022 was $8.477B, a 1.78% decline from 2021.
- Becton Dickinson annual gross profit for 2021 was $8.631B, a 26.96% increase from 2020.
Becton Dickinson Annual Gross Profit
(Millions of US $) |
| 2023 |
$8,170 |
| 2022 |
$8,477 |
| 2021 |
$8,631 |
| 2020 |
$6,798 |
| 2019 |
$8,288 |
| 2018 |
$7,269 |
| 2017 |
$5,965 |
| 2016 |
$5,991 |
| 2015 |
$4,695 |
| 2014 |
$4,301 |
| 2013 |
$4,171 |
| 2012 |
$3,953 |
| 2011 |
$3,959 |
| 2010 |
$3,696 |
| 2009 |
$3,675 |
Becton Dickinson Quarterly Gross Profit
(Millions of US $) |
| 2024-06-30 |
$2,307 |
| 2024-03-31 |
$2,304 |
| 2023-12-31 |
$2,027 |
| 2023-09-30 |
$1,702 |
| 2023-06-30 |
$2,100 |
| 2023-03-31 |
$2,235 |
| 2022-12-31 |
$2,133 |
| 2022-09-30 |
$2,077 |
| 2022-06-30 |
$2,067 |
| 2022-03-31 |
$2,113 |
| 2021-12-31 |
$2,220 |
| 2021-09-30 |
$1,695 |
| 2021-06-30 |
$1,958 |
| 2021-03-31 |
$2,246 |
| 2020-12-31 |
$2,732 |
| 2020-09-30 |
$1,427 |
| 2020-06-30 |
$1,660 |
| 2020-03-31 |
$1,733 |
| 2019-12-31 |
$1,978 |
| 2019-09-30 |
$2,267 |
| 2019-06-30 |
$2,074 |
| 2019-03-31 |
$1,974 |
| 2018-12-31 |
$1,973 |
| 2018-09-30 |
$2,094 |
| 2018-06-30 |
$2,016 |
| 2018-03-31 |
$1,606 |
| 2017-12-31 |
$1,553 |
| 2017-09-30 |
$1,578 |
| 2017-06-30 |
$1,503 |
| 2017-03-31 |
$1,432 |
| 2016-12-31 |
$1,452 |
| 2016-09-30 |
$1,553 |
| 2016-06-30 |
$1,547 |
| 2016-03-31 |
$1,483 |
| 2015-12-31 |
$1,408 |
| 2015-09-30 |
$1,430 |
| 2015-06-30 |
$1,174 |
| 2015-03-31 |
$1,046 |
| 2014-12-31 |
$1,045 |
| 2014-09-30 |
$1,102 |
| 2014-06-30 |
$1,111 |
| 2014-03-31 |
$1,053 |
| 2013-12-31 |
$1,035 |
| 2013-09-30 |
$1,087 |
| 2013-06-30 |
$1,060 |
| 2013-03-31 |
$1,018 |
| 2012-12-31 |
$1,006 |
| 2012-09-30 |
$1,001 |
| 2012-06-30 |
$1,033 |
| 2012-03-31 |
$988 |
| 2011-12-31 |
$931 |
| 2011-09-30 |
$952 |
| 2011-06-30 |
$1,029 |
| 2011-03-31 |
$1,001 |
| 2010-12-31 |
$977 |
| 2010-09-30 |
$839 |
| 2010-06-30 |
$947 |
| 2010-03-31 |
$935 |
| 2009-12-31 |
$974 |
| 2009-09-30 |
$898 |
| 2009-06-30 |
$960 |
| 2009-03-31 |
$896 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$69.388B |
$19.372B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
